Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
MousePhenoabnormal circulating sodium level

DNAAF2 SVEP1 TMEM151B TENM4

1.08e-04201184MP:0001776
MousePhenoabnormal sodium level

DNAAF2 SVEP1 TMEM151B TENM4

2.18e-04241184MP:0020889
MousePhenoabnormal sodium ion homeostasis

DNAAF2 SVEP1 TMEM151B TENM4

2.36e-04246184MP:0011977
DomainPTX

PTX4 SVEP1

5.93e-0510222SM00159
DomainPentaxin-related

PTX4 SVEP1

7.24e-0511222IPR001759
DomainPentaxin

PTX4 SVEP1

7.24e-0511222PF00354
DomainSushi

CFHR1 SVEP1

1.69e-0352222PF00084
DomainCCP

CFHR1 SVEP1

1.83e-0354222SM00032
DomainSUSHI

CFHR1 SVEP1

1.96e-0356222PS50923
DomainSushi_SCR_CCP_dom

CFHR1 SVEP1

2.03e-0357222IPR000436
DomainEGF_extracell

SVEP1 TENM4

2.25e-0360222IPR013111
DomainEGF_2

SVEP1 TENM4

2.25e-0360222PF07974
Domain-

PTX4 SVEP1

5.53e-03952222.60.120.200
DomainPDZ

MAST3 PATJ

1.18e-02141222PF00595
DomainPDZ

MAST3 PATJ

1.30e-02148222SM00228
Domain-

MAST3 PATJ

1.33e-021502222.30.42.10
DomainPDZ

MAST3 PATJ

1.35e-02151222PS50106
DomainPDZ

MAST3 PATJ

1.37e-02152222IPR001478
Pubmed

Lulu2 regulates the circumferential actomyosin tensile system in epithelial cells through p114RhoGEF.

ARHGEF18 PATJ

1.17e-05823222006950
Pubmed

Identification of potential nuclear reprogramming and differentiation factors by a novel selection method for cloning chromatin-binding proteins.

PPP2R3B SVEP1

1.17e-05823215522233
Pubmed

Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder.

SVEP1 TENM4

7.10e-051923218711365
GeneFamilyHyalectan proteoglycans|V-set domain containing|Sushi domain containing|C-type lectin domain containing

CFHR1 SVEP1

6.32e-04571221179
GeneFamilyPDZ domain containing

MAST3 PATJ

4.39e-031521221220
DrugDiloxanide furoate [3736-81-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A

MIIP C10orf95 MAST3 MARK4

3.45e-051872345025_UP
DrugDehydroisoandosterone 3-acetate [853-23-6]; Up 200; 12.2uM; MCF7; HT_HG-U133A

MIIP C10orf95 SVEP1 MARK4

3.53e-051882345019_UP
DrugHomochlorcyclizine dihydrochloride [1982-36-1]; Up 200; 10.4uM; MCF7; HT_HG-U133A

PTCRA FGF6 SVEP1 MAST3

3.75e-051912347417_UP
DrugIodixanol [92339-11-2]; Up 200; 2.6uM; MCF7; HT_HG-U133A

DNAAF2 C10orf95 PIK3R5 PATJ

4.07e-051952344848_UP
DrugLisuride (S)(-) [18016-80-3]; Up 200; 11.8uM; MCF7; HT_HG-U133A

MIIP C10orf95 MAST3 MARK4

4.07e-051952345028_UP
DrugHomosalate [118-56-9]; Down 200; 15.2uM; PC3; HT_HG-U133A

MIIP MAST3 MARK4 PATJ

4.07e-051952344533_DN
DrugNifedipine [21829-25-4]; Up 200; 11.6uM; MCF7; HT_HG-U133A

MIIP PTCRA FGF6 MARK4

4.07e-051952346006_UP
DrugMolindone hydrochloride [15622-65-8]; Up 200; 12.8uM; MCF7; HT_HG-U133A

ADGRB2 FGF6 FAM131A MARK4

4.15e-051962347337_UP
DrugPF-00539758-00 [351321-34-1]; Up 200; 10uM; MCF7; HT_HG-U133A

ADGRB2 MIIP PTCRA TENM4

4.15e-051962346416_UP
Drugaspirin, USP; Up 200; 100uM; MCF7; HT_HG-U133A

FAM131A MAST3 MARK4 PATJ

4.23e-051972346964_UP
DrugPiperidolate hydrochloride [129-77-1]; Up 200; 11.2uM; MCF7; HT_HG-U133A

FGF6 C10orf95 SVEP1 MARK4

4.23e-051972346772_UP
DrugAlfuzosin hydrochloride [81403-68-1]; Up 200; 9.4uM; MCF7; HT_HG-U133A

PTCRA FGF6 C10orf95 PIK3R5

4.23e-051972345242_UP
DrugGlycocholic acid [475-31-0]; Up 200; 8.6uM; MCF7; HT_HG-U133A

C10orf95 MAST3 MARK4 PATJ

4.32e-051982345316_UP
DrugTalampicillin hydrochloride [39878-70-1]; Up 200; 7.8uM; MCF7; HT_HG-U133A

PTCRA PIK3R5 FAM131A SVEP1

4.32e-051982343515_UP
DrugClozapine [5786-21-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A

FGF6 C10orf95 FAM131A MARK4

4.32e-051982342644_UP
DrugAmpyrone [83-07-8]; Up 200; 19.6uM; HL60; HG-U133A

ADGRB2 MIIP PTCRA FGF6

4.32e-051982341402_UP
DrugTetracaone hydrochloride [136-47-0]; Up 200; 13.2uM; MCF7; HT_HG-U133A

MIIP FGF6 MAST3 MARK4

4.32e-051982347473_UP
DrugFlurbiprofen [5104-49-4]; Down 200; 16.4uM; MCF7; HT_HG-U133A

MIIP PTCRA MARK4 PATJ

4.32e-051982346472_DN
DrugAzapropazone [13539-59-8]; Up 200; 13.4uM; MCF7; HT_HG-U133A

MIIP C10orf95 TENM4 PATJ

4.32e-051982346522_UP
DrugPicrotoxinin [17617-45-7]; Up 200; 13.6uM; MCF7; HT_HG-U133A

FGF6 C10orf95 SVEP1 MARK4

4.32e-051982344842_UP
DrugRemoxipride Hydrochloride [73220-03-8]; Down 200; 9.8uM; MCF7; HT_HG-U133A

C10orf95 MAST3 MARK4 PATJ

4.40e-051992345443_DN
DrugPrilocaine hydrochloride [1786-81-8]; Up 200; 15.6uM; MCF7; HT_HG-U133A

PTCRA PIK3R5 SVEP1 MARK4

4.40e-051992344749_UP
DrugFlurbiprofen [5104-49-4]; Up 200; 16.4uM; MCF7; HT_HG-U133A

PTCRA FGF6 PIK3R5 FAM131A

4.40e-051992345269_UP
DrugIdazoxan hydrochloride [79944-56-2]; Down 200; 16.6uM; MCF7; HT_HG-U133A

MIIP C10orf95 MARK4 PATJ

4.40e-051992346465_DN
DrugCarbamazepine [298-46-4]; Up 200; 17uM; MCF7; HT_HG-U133A

C10orf95 PIK3R5 MARK4 PATJ

4.49e-052002341683_UP
DrugDimaprit dihydrochloride [23256-33-9]; Up 200; 17uM; MCF7; HT_HG-U133A

MIIP FGF6 FAM131A MARK4

4.49e-052002347480_UP
Drugcyclofenil

PTCRA CFHR1

4.46e-0431232CID000002898
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A

ADGRB2 MAST3 MARK4

7.30e-041772335745_UP
DrugDiethylstilbestrol [56-53-1]; Up 200; 15uM; MCF7; HT_HG-U133A

ADGRB2 PTCRA SVEP1

7.54e-041792333895_UP
Drugwortmannin from Penicillium funiculosum; Up 200; 0.01uM; MCF7; HT_HG-U133A

PTCRA MARK4 PATJ

8.04e-041832331668_UP
Drugtrichostatin A; Up 200; 0.1uM; MCF7; HG-U133A

ARHGEF18 MAST3 MARK4

8.42e-04186233332_UP
DrugGanciclovir [82410-32-0]; Down 200; 15.6uM; MCF7; HT_HG-U133A

C10orf95 FAM131A PATJ

8.55e-041872333368_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

MIIP TENM4 PATJ

8.55e-041872336671_DN
DrugMianserine hydrochloride [21535-47-7]; Up 200; 13.2uM; MCF7; HT_HG-U133A

ADGRB2 FAM131A SVEP1

8.82e-041892332231_UP
Drugwortmannin from Penicillium funiculosum; Up 200; 0.01uM; MCF7; HT_HG-U133A

MIIP C10orf95 PATJ

8.82e-041892337002_UP
Drugcolchicine; Up 200; 1uM; SKMEL5; HG-U133A

PTCRA FAM131A MARK4

8.96e-04190233630_UP
DrugStrophantine octahydrate [11018-89-6]; Down 200; 5.4uM; PC3; HT_HG-U133A

DNAAF2 MARK4 PATJ

8.96e-041902336680_DN
DrugMeclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; MCF7; HT_HG-U133A

PTCRA MAST3 PATJ

9.09e-041912333605_DN
DrugLanatoside C [17575-22-3]; Down 200; 4uM; PC3; HT_HG-U133A

MIIP DNAAF2 MAST3

9.09e-041912334328_DN
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A

ADGRB2 PTCRA MARK4

9.09e-041912334302_UP
DrugClindamycin hydrochloride [21462-39-5]; Up 200; 8.6uM; MCF7; HT_HG-U133A

ADGRB2 PTCRA SVEP1

9.23e-041922332219_UP
Drug0317956-0000 [391210-11-0]; Down 200; 1uM; MCF7; HT_HG-U133A

MIIP DNAAF2 FAM131A

9.23e-041922333858_DN
DrugHexetidine [141-94-6]; Down 200; 11.8uM; MCF7; HT_HG-U133A

C10orf95 MARK4 PATJ

9.23e-041922333318_DN
DrugPiperine [94-62-2]; Down 200; 14uM; MCF7; HT_HG-U133A

MIIP FAM131A MARK4

9.37e-041932333263_DN
DrugDilazep dihydrochloride [20153-98-4]; Down 200; 6uM; MCF7; HT_HG-U133A

MIIP MAST3 MARK4

9.37e-041932332294_DN
DrugGabapentin [60142-96-3]; Up 200; 23.4uM; MCF7; HT_HG-U133A

MIIP PTCRA FGF6

9.37e-041932337229_UP
DrugAspartic acid, N-acetyl (R,S) [997-55-7]; Up 200; 22.8uM; MCF7; HT_HG-U133A

MIIP SVEP1 MAST3

9.37e-041932334125_UP
DrugSTOCK1N-35215; Down 200; 10uM; MCF7; HT_HG-U133A

DNAAF2 FAM131A MARK4

9.37e-041932336422_DN
DrugTestosterone propionate [57-85-2]; Up 200; 11.6uM; MCF7; HT_HG-U133A

MIIP PTCRA FAM131A

9.37e-041932335271_UP
DrugMuramic acid, N-acetyl [10597-89-4]; Up 200; 13.6uM; MCF7; HT_HG-U133A

C10orf95 MAST3 MARK4

9.37e-041932333262_UP
DrugAzacyclonol [115-46-8]; Up 200; 15uM; MCF7; HT_HG-U133A

FGF6 PIK3R5 MAST3

9.51e-041942335398_UP
DrugAvermectin B1 [71751-41-2]; Down 200; 4.8uM; MCF7; HT_HG-U133A

C10orf95 MARK4 PATJ

9.51e-041942336081_DN
DrugEquilin [474-86-2]; Down 200; 15uM; MCF7; HT_HG-U133A

PTCRA C10orf95 FAM131A

9.51e-041942333377_DN
DrugDiltiazem hydrochloride [33286-22-5]; Up 200; 8.8uM; PC3; HT_HG-U133A

IGLL5 MAST3 PATJ

9.51e-041942336710_UP
DrugPirenperone [ 75444-65-4]; Down 200; 10.2uM; MCF7; HT_HG-U133A

C10orf95 MARK4 PATJ

9.51e-041942333316_DN
DrugAcyclovir [59277-89-3]; Down 200; 17.8uM; MCF7; HT_HG-U133A

MAST3 MARK4 PATJ

9.51e-041942335278_DN
DrugIopanoic acid [96-83-3]; Down 200; 7uM; MCF7; HT_HG-U133A

MIIP MARK4 PATJ

9.51e-041942335448_DN
DrugCefaclor [70356-03-5]; Up 200; 10.4uM; MCF7; HT_HG-U133A

PTCRA MAST3 MARK4

9.51e-041942334967_UP
DrugCyclosporin A [59865-13-3]; Down 200; 3.4uM; MCF7; HT_HG-U133A

PTCRA MAST3 MARK4

9.51e-041942334411_DN
DrugKynurenine, 3-hydroxy (R,S) [2147-61-7]; Down 200; 17.8uM; MCF7; HT_HG-U133A

MIIP C10orf95 PATJ

9.51e-041942335641_DN
DrugRapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A

FAM131A MAST3 MARK4

9.51e-041942336958_DN
DrugNefopam hydrochloride [23327-57-3]; Down 200; 13.8uM; MCF7; HT_HG-U133A

MIIP C10orf95 MARK4

9.66e-041952332317_DN
DrugCP-320650-01 [172079-28-6]; Up 200; 1uM; MCF7; HT_HG-U133A

MIIP FGF6 MARK4

9.66e-041952334382_UP
DrugTiaprofenic acid [33005-95-7]; Down 200; 15.4uM; MCF7; HT_HG-U133A

MIIP FAM131A MARK4

9.66e-041952332852_DN
DrugDipyridamole [58-32-2]; Up 200; 8uM; MCF7; HT_HG-U133A

C10orf95 SVEP1 MARK4

9.66e-041952331517_UP
DrugCiprofibrate [52214-84-3]; Up 200; 13.8uM; PC3; HT_HG-U133A

ADGRB2 PTCRA PIK3R5

9.66e-041952335740_UP
DrugBumetanide [28395-03-1]; Down 200; 11uM; HL60; HT_HG-U133A

PTCRA PIK3R5 MARK4

9.66e-041952332409_DN
DrugMetronidazole [443-48-1]; Up 200; 23.4uM; MCF7; HT_HG-U133A

MIIP PIK3R5 MAST3

9.66e-041952334141_UP
DrugHydralazine hydrochloride [304-20-1]; Down 200; 20.4uM; MCF7; HT_HG-U133A

MIIP FAM131A MAST3

9.66e-041952332311_DN
DrugTiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Up 200; 6.4uM; PC3; HT_HG-U133A

MIIP PTCRA SVEP1

9.66e-041952332096_UP
DrugHomosalate [118-56-9]; Up 200; 15.2uM; MCF7; HT_HG-U133A

MIIP PTCRA TENM4

9.66e-041952334355_UP
DrugPhenacetin [62-44-2]; Down 200; 22.4uM; PC3; HT_HG-U133A

MARK4 TENM4 PATJ

9.66e-041952333992_DN
DrugBumetanide [28395-03-1]; Down 200; 11uM; PC3; HT_HG-U133A

ADGRB2 PRPF40A MARK4

9.66e-041952335117_DN
DrugCytisine (-) [485-35-8]; Down 200; 21uM; PC3; HT_HG-U133A

MIIP SVEP1 MAST3

9.66e-041952335739_DN
DrugCimetidine [51481-61-9]; Up 200; 15.8uM; PC3; HT_HG-U133A

ADGRB2 PTCRA C10orf95

9.66e-041952334063_UP
DrugDihydroergocristine mesylate [24730-10-7]; Up 200; 5.6uM; MCF7; HT_HG-U133A

C10orf95 PIK3R5 PATJ

9.66e-041952337034_UP
DrugHydrastine hydrochloride [5936-28-7]; Up 200; 9.6uM; PC3; HT_HG-U133A

MIIP FGF6 MARK4

9.66e-041952337309_UP
DrugEsculetin [305-01-1]; Down 200; 22.4uM; HL60; HT_HG-U133A

MIIP PTCRA MARK4

9.66e-041952333120_DN
Drug3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; PC3; HT_HG-U133A

FAM131A MAST3 PATJ

9.66e-041952334664_DN
DrugHarmaline hydrochloride dihydrate [6027-98-1]; Up 200; 14uM; MCF7; HT_HG-U133A

MAST3 MARK4 TENM4

9.66e-041952332805_UP
DrugHecogenin [467-55-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A

MIIP FGF6 PATJ

9.66e-041952337175_UP
DrugSulindac [38194-50-2]; Down 200; 11.2uM; PC3; HT_HG-U133A

ADGRB2 MAST3 MARK4

9.66e-041952335103_DN
DrugAlfaxalone [23930-19-0]; Down 200; 12uM; HL60; HT_HG-U133A

MIIP DNAAF2 MARK4

9.66e-041952333135_DN
DrugFurazolidone [67-45-8]; Down 200; 17.8uM; MCF7; HT_HG-U133A

PTCRA C10orf95 MARK4

9.66e-041952333358_DN
DrugEthosuximide [77-67-8]; Down 200; 28.4uM; MCF7; HT_HG-U133A

PTCRA MARK4 PATJ

9.80e-041962332280_DN
DrugCoralyne chloride hydrate [38989-38-7]; Down 200; 9.6uM; MCF7; HT_HG-U133A

MIIP C10orf95 PATJ

9.80e-041962335418_DN
DrugS-(+)-ibuprofen [51146-56-6]; Down 200; 19.4uM; HL60; HT_HG-U133A

MIIP IGLL5 MARK4

9.80e-041962333094_DN
DrugGemfibrozil [25812-30-0]; Up 200; 16uM; MCF7; HT_HG-U133A

PTCRA PIK3R5 MARK4

9.80e-041962335488_UP
DrugAmiodarone hydrochloride [19774-82-4]; Up 200; 5.8uM; MCF7; HT_HG-U133A

MIIP PTCRA FAM131A

9.80e-041962335253_UP
DrugPicotamide monohydrate [80530-63-8]; Up 200; 10.2uM; MCF7; HT_HG-U133A

ADGRB2 MIIP MARK4

9.80e-041962332233_UP
DrugXylometazoline hydrochloride [1218-35-5]; Up 200; 14.2uM; MCF7; HT_HG-U133A

ADGRB2 FGF6 MARK4

9.80e-041962332270_UP
DrugGlipizide [29094-61-9]; Up 200; 9uM; MCF7; HT_HG-U133A

SVEP1 MARK4 PATJ

9.80e-041962331508_UP
DrugPropafenone hydrochloride [34183-22-7]; Up 200; 10.6uM; MCF7; HT_HG-U133A

MIIP C10orf95 MARK4

9.80e-041962332871_UP
DrugIpratropium bromide [22254-24-6]; Up 200; 9.8uM; MCF7; HT_HG-U133A

PTCRA MAST3 TENM4

9.80e-041962332762_UP
DrugCefaclor [70356-03-5]; Down 200; 10.4uM; MCF7; HT_HG-U133A

MIIP MARK4 PATJ

9.80e-041962332843_DN
DrugPizotifen malate [5189-11-7]; Down 200; 9.4uM; HL60; HT_HG-U133A

MIIP PTCRA MAST3

9.80e-041962333134_DN
DrugFluvastatin sodium salt [93957-55-2]; Down 200; 9.2uM; MCF7; HT_HG-U133A

MIIP DNAAF2 PATJ

9.80e-041962335290_DN
DrugTimolol maleate salt [26921-17-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A

C10orf95 FAM131A MARK4

9.80e-041962336483_DN
DrugEthotoin [86-35-1]; Down 200; 19.6uM; MCF7; HT_HG-U133A

PTCRA C10orf95 SVEP1

9.80e-041962334366_DN
DrugPhentolamine hydrochloride [73-05-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A

C10orf95 FAM131A MARK4

9.80e-041962333971_DN
Diseaseatrophic macular degeneration, age-related macular degeneration, wet macular degeneration

CFHR1 MARK4

7.55e-0460202EFO_0001365, EFO_0004683, EFO_1001492
Diseaseeosinophil percentage of leukocytes

ARHGEF18 PIK3R5 MAST3 MARK4

1.42e-03746204EFO_0007991
DiseaseBell's palsy

TENM4 PATJ

2.16e-03102202EFO_0007167
Diseaseserum alanine aminotransferase measurement

MAST3 MARK4 TENM4 PATJ

2.48e-03869204EFO_0004735
Diseaseeosinophil count

ARHGEF18 PIK3R5 SVEP1 MAST3 MARK4

2.66e-031488205EFO_0004842
Diseaseglycine measurement

MAST3 TENM4

3.85e-03137202EFO_0009767
DiseaseSclerocystic Ovaries

PTCRA TMEM151B

4.24e-03144202C1136382
DiseasePolycystic Ovary Syndrome

PTCRA TMEM151B

4.24e-03144202C0032460
Diseasegait measurement

ADGRB2 MAST3

4.59e-03150202EFO_0007680
Diseaseage at menarche

PRPF40A LRRC53 MAST3

7.17e-03594203EFO_0004703
Diseasehealth study participation

MAST3 MARK4

7.63e-03195202EFO_0010130
DiseaseCalcium channel blocker use measurement

ARHGEF18 SVEP1

9.05e-03213202EFO_0009930

Protein segments in the cluster

PeptideGeneStartEntry
GSWSLCSRSCGRGSR

ADGRB2

371

O60241
SSLAGSQDLSRRRSW

ARHGEF18

66

Q6ZSZ5
SRGWGTLLSRSRAGL

FGF6

51

P10767
SWSGRITCAELRRSS

PPP2R3B

276

Q9Y5P8
WCSRSALRAPSSSLG

PTCRA

251

Q6ISU1
SSRSLAWGSSAGRES

DNAAF2

471

Q9NVR5
TLRGSWFRNTSGLTR

LRRC53

121

A6NM62
RRLSGSSLCSGSWVS

PRPF40A

31

O75400
VGSSRSSLRSLWGRL

IGLL5

56

B9A064
SRQRSGWSSGRSGRS

DDX50

676

Q9BQ39
SLGSARTLRGWSRSS

FAM131A

51

Q6UXB0
PSWSSRSLGARCRNS

MARK4

31

Q96L34
RLRSWTSSGSSCQSS

MAST3

751

O60307
LSSRSHTLRTTCWDG

CFHR1

306

Q03591
SWVRTASGRLGTLLS

PTX4

301

Q96A99
RLLSWHRTCGTSSES

PLD6

236

Q8N2A8
GSRRSCLWRSRSGSV

TMEM151B

481

Q8IW70
SLSTSCPRGRSSVWG

MIIP

61

Q5JXC2
SRRCLSNGSWSGSSP

SVEP1

2986

Q4LDE5
RRRACSSPTTAWSGA

C10orf95

216

Q9H7T3
LSRRSTSWSAGLCLN

PIK3R5

26

Q8WYR1
IGRLRAGSWTSARTT

PATJ

1611

Q8NI35
LWGRSTRSGRSSCLS

TENM4

131

Q6N022